Life Sciences Venture Capital Monitor – Europe 04/2023 published

thumbnail of 2023-05-05 – FCF Life Sciences Venture Capital Monitor – Europe – 04-2023

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 04/2023”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of April 2023 we identify the following current VC trends in Europe:

  • In 2023, overall Life Sciences funding has reached EUR 2,446m
  • Top 5 Deals exceed EUR 90m each, largest transaction amounted to EUR 138m in Distalmotion (Switzerland)
  • Revival Healthcare Capital (United States) dominates the Top 5 Investors (by deal volume), followed by Novo Holdings (Denmark) and Gilde Healthcare Partners (Netherlands)
  • Biotech received 53% of the total investment volume (+3% compare to the previous month)
  • Oncology dominates as the top indication in Biotechnology

To access the full report, please click here.

By Dr. Mathias SchottJohannes Link and Marco Buonafede-Bennardo.